Physicians at the Winship Cancer Institute of Emory University administered the first investigational in vivo CAR-T therapy dose in the United States for patients with relapsed or refractory multiple myeloma. The program targets multiple myeloma using an in vivo CAR-T approach, designed to deliver CAR components inside the body rather than manufacturing an engineered cell product. Trial investigators framed the administration as a step in the next generation of cellular immunotherapy for harder-to-treat relapsed settings. The announcement positions the Emory/Winship team among the early US adopters of in vivo CAR-T trials, a category that could reshape manufacturing timelines and access if efficacy and safety track in future study phases.